Clinical evaluation ofProstaglandin E1liposome in treatment ofPatients with unstable anginaPectoris

Abstract

Abstract: AIM: To evaluate the clinical effects ofProstaglandin E1liposome(LipoPGE₁)onPatients with unstable anginaPectoris.METHODS: 54Patients with unstable anginaPectoris(UAP)were randomly assigned to two groups:26Patients treated with one-isosorbide dinitrate in control group,and 28Patients treated withlipoPGE1 in treatment group.The clinical efficacy and hemorheological changes were observed.RESULTS: The total effective rates of symptom and ECG were no significance(P>0.05)between control grouPand treatment group.The relapse rates of two weeks were different remarkably(P<0.05)between the two groups after treatment.The improvement of the hemorheological indexes was significantly inlipoPGE1 group.CONCLUSION: LipoPGE1 is reliable in treatment ofPatients with unstable anginaPectoris.

Key words: pharmacodynamics, prostaglandin E1liposome, unstable anginaPectoris, hemorheology, oneisosorbide dinitrate

CLC Number:

R969.4
R972

XIA Chao-Hong, YANG Yu-Wen, WANG Xing, CHEN Yue-Yun. Clinical evaluation ofProstaglandin E1liposome in treatment ofPatients with unstable anginaPectoris[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(4): 459-461.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[3]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[4]	XU Liying, ZHANG Gaosong, HUANG Xiaomin, HUANG Jihan, WANG Shuhua. Clinical efficacy and modeling evaluation of He-wei-zhi-xie capsules in treating diarrhea patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 47-55.
[5]	JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
[6]	LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun. Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
[7]	XIANG Rongfeng, SUN Fengjun, XIONG Lirong, YU Mingjie, DAI Qing, CHEN Yongchuan. Pharmacokinetics and pharmacodynamics of (S)-pantoprazole sodium enteric-coated tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 903-909.
[8]	WU Juan, ZHANG He, FENG Guilin. Agkistrodon halys venom platelet inhibitor inhibits GPVI expression and changes hemorheology in rats with acute myocardial ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 49-54.
[9]	LI Jian, YANG Jinbo, WANG Yuzhu. Applications of model-informed drug development (MIDD) on new drug research and development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
[10]	CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia. Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.
[11]	MA Guangli, XU Ling, CHEN Rui, CHEN Yuancheng, ZHAO Wei, LIU Dongyang, JIAO Zheng, LI Jian, JI Shuangmin, LI Li, LI Liang, WANG Yuzhu, YANG Jinbo, WANG Yaning, SUN He, HU Pei, ZHENG Qingshan, LU Wei. General considerations of population pharmacokinetic/pharmacodynamic study in new drug development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1201-1220.
[12]	LIAN Yanhong, JIANG Huifang, YUAN Xiaohong, ZHOU Huidan, XIE Kangjie, FANG Jun, JIN Xiaoju. Effects of neoadjuvant chemotherapy on the pharmacodynamics of rocuronium bromide in patients undergoing gastric cancer surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1161-1164.
[13]	ZHANG Chao . Pharmacodynamic studies evaluation of voriconazole [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 116-120.
[14]	WU Yonglei, WANG Dan, ZHANG Suiyang, WANG Ying, SUN Qin. Pharmacokinetics and pharmacodynamics of meropene administered by traditional prolonged infusion or optimized prolonged infusion in different tissues of septic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 767-774.
[15]	ZHU Wen-jing, CUI Wei-hua, WANG Shao-hua, ZHANG Yuan-yuan, GAO Ji-jun. Development of moxifloxacin in treating community-acquired pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 597-600.

Clinical evaluation ofProstaglandin E1liposome in treatment ofPatients with unstable anginaPectoris

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments